122 related articles for article (PubMed ID: 30595458)
1. Safety and Survival Associated with Biologic Therapies: First Report of the Biobadaguay on the Paraguayan-Uruguayan Registry of Adverse Events with Biologic Therapies.
de Abreu P; Ávila-Pedretti G; Morel Z; Acosta MI; Cabrera-Villalba S; Melgarejo P; Franco M; Delgadillo P; Román L; Elizaur JG; Paredes E; Cordovilla DO; Palleiro D; Albanese M; Mazzoleni J
Reumatol Clin (Engl Ed); 2020; 16(5 Pt 2):396-404. PubMed ID: 30595458
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
3. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
4. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
6. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients.
Romano M; Pontikaki I; Gattinara M; Ardoino I; Donati C; Boracchi P; Meroni PL; Gerloni V
Reumatismo; 2014 Mar; 65(6):278-85. PubMed ID: 24705031
[TBL] [Abstract][Full Text] [Related]
7. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
Sakai R; Tanaka M; Nanki T; Watanabe K; Yamazaki H; Koike R; Nagasawa H; Amano K; Saito K; Tanaka Y; Ito S; Sumida T; Ihata A; Ishigatsubo Y; Atsumi T; Koike T; Nakajima A; Tamura N; Fujii T; Dobashi H; Tohma S; Sugihara T; Ueki Y; Hashiramoto A; Kawakami A; Hagino N; Miyasaka N; Harigai M;
Ann Rheum Dis; 2012 Nov; 71(11):1820-6. PubMed ID: 22504558
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
[TBL] [Abstract][Full Text] [Related]
9. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
[TBL] [Abstract][Full Text] [Related]
11. Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0.
Ventura-Ríos L; Bañuelos-Ramírez D; Hernández-Quiroz Mdel C; Robles-San Román M; Irazoque-Palazuelos F; Goycochea-Robles MV
Reumatol Clin; 2012; 8(4):189-94. PubMed ID: 22673388
[TBL] [Abstract][Full Text] [Related]
12. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.
Horák P; Skácelová M; Hejduk K; Smržová A; Pavelka K
Clin Rheumatol; 2013 Oct; 32(10):1451-8. PubMed ID: 23728498
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
14. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
Woodrick RS; Ruderman EM
Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628
[TBL] [Abstract][Full Text] [Related]
15. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.
McErlane F; Foster HE; Davies R; Lunt M; Watson KD; Symmons DP; Hyrich KL
Rheumatology (Oxford); 2013 Oct; 52(10):1905-13. PubMed ID: 23873820
[TBL] [Abstract][Full Text] [Related]
16. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
Nisar MK; Rafiq A; Östör AJ
Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
[TBL] [Abstract][Full Text] [Related]
17. Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study.
Kojima T; Kaneko A; Hirano Y; Ishikawa H; Miyake H; Oguchi T; Takagi H; Yabe Y; Kato T; Ito T; Terabe K; Fukaya N; Kanayama Y; Shioura T; Funahashi K; Hayashi M; Kato D; Matsubara H; Fujibayashi T; Kojima M; Ishiguro N;
Mod Rheumatol; 2012 Jun; 22(3):339-45. PubMed ID: 21892671
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
[TBL] [Abstract][Full Text] [Related]
19. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis.
Cecchin V; Zannin ME; Ferrari D; Pontikaki I; Miserocchi E; Paroli MP; Bracaglia C; Marafon DP; Pastore S; Parentin F; Simonini G; De Libero C; Falcini F; Petaccia A; Filocamo G; De Marco R; La Torre F; Guerriero S; Martino S; Comacchio F; Muratore V; Martini G; Vittadello F; Zulian F
J Rheumatol; 2018 Aug; 45(8):1167-1172. PubMed ID: 29657140
[TBL] [Abstract][Full Text] [Related]
20. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
